EverPoint Asset Management’s Gilead Sciences GILD Stock Holding History

EverPoint Asset Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-125,000	Closed	-$9.89M	–	449
2016 Q3	$9.89M	Sell	125,000 -575,000	-82%	-$46.7M	0.18%	154
2016 Q2	$58.4M	Buy	700,000 +600,000	+600%	+$53.2M	1.15%	10
2016 Q1	$9.19M	Buy	+100,000	New	+$9.02M	0.18%	146
2015 Q2	–	Sell	-410,000	Closed	-$40.2M	–	502
2015 Q1	$40.2M	Buy	410,000 +180,000	+78%	+$18.3M	0.76%	21
2014 Q4	$21.7M	Buy	+230,000	New	+$23.8M	0.49%	58

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

EverPoint Asset Management's GILD Position: Q4 2016 in Review

EverPoint Asset Management sold out of Gilead Sciences (GILD) in Q4 2016, closing a stake of 125,000 shares — an estimated $9.89M sold.

EverPoint Asset Management first reported a position in GILD in Q4 2014 and held it in 5 quarters. The position peaked at $58.4M in Q2 2016. 1,573 funds tracked by Wall St. Rank hold GILD as of Q4 2016.

EverPoint Asset Management reported no remaining Gilead Sciences position as of Q4 2016 after selling out during the quarter.
EverPoint Asset Management sold 125,000 Gilead Sciences shares in Q4 2016, an estimated $9.89M.
EverPoint Asset Management first reported a position in Gilead Sciences in Q4 2014 and held it in 5 quarters.
EverPoint Asset Management's Gilead Sciences position peaked at $58.4M in Q2 2016.
1,573 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.